QUATTROTURBO, NCT02309450: Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen |
|
|
| Withdrawn | 2 | 0 | Europe | .Asunaprevir, Daclatasvir and BMS - 791325 | ANRS, Emerging Infectious Diseases, Bristol-Myers Squibb | Hepatitis C Virus Genotype 4 Infection | 11/15 | 08/16 | | |
